TD Cowen analyst Tara Bancroft initiated coverage of Verona Pharma (VRNA) with a Buy rating and $100 price target The firm says Ohtuvayre’s early momentum is “refreshing to see in this environment,” and should continue with a slight beat in Q1. TD’s $340M 2025 estimate and peak estimate of $3.9B suggest robust use, but key opinion leaders believe it could achieve 10-times and 5-times higher penetration in the same timeframes, respectively, and “there are multiple upside levers,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Promising Growth and Market Potential of Verona Pharma’s Ohtuvayre Drives Buy Rating
- Is VRNA a Buy, Before Earnings?
- Amazon downgraded, Netflix upgraded: Wall Street’s top analyst calls
- Cantor starts Verona at Overweight, says momentum ‘just getting started’
- Verona Pharma initiated with an Overweight at Cantor Fitzgerald